SEC Tracker
Get the app

Oruka Therapeutics ORKA

Fairmount Healthcare Fund II (Director, 10% Stockholder) plans to sell 3,553,410 ORKA shares, about $300M

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Jul 1, 2026
  2. Broker: Goldman Sachs & Co. LLC
  3. Shares acquired by: Conversion of Series B Non-Voting Convertible Preferred Stock

All of Fairmount Healthcare Fund II's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 3,553,410 shares at $84.43 on Jul 1, 2026 · Form 4

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Oruka Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. CytomX Therapeutics CTMX public float $372M, Jun 30, 2025
  2. Cronos Group CRON public float $380M, Jun 30, 2025
  3. REGENXBIO RGNX public float $385M, Jun 30, 2025
  4. Capricor Therapeutics CAPR public float $399M, Jun 30, 2025
  5. Cryoport CYRX public float $400M, Jun 30, 2025